brain health News
-
Sage Therapeutics to Present at the Piper Sandler 34th Annual Healthcare Conference
Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, announced today that the Company will present at the Piper Sandler 34th Annual Healthcare Conference on Thursday, December 1, 2022, at 8:00 a.m. ET in New York, NY. A live webcast of the presentation can be accessed on the Investor page of Sage’s website at ...
-
Sage Therapeutics to Present at Morgan Stanley 20th Annual Global Healthcare Conference
Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, announced today that the Company will present at the Morgan Stanley 20th Annual Global Healthcare Conference on Monday, September 12, 2022, at 3:40 p.m. ET in New York, NY. A live webcast of the presentation can be accessed on the Investor page of Sage’s website ...
-
Sage Therapeutics to Present at the Stifel 2022 Healthcare Conference
Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, announced today that the Company will present at the Stifel 2022 Healthcare Conference on Wednesday, November 16, 2022, at 10:55 a.m. ET in New York, NY. A live webcast of the presentation can be accessed on the Investor page of Sage’s website at ...
-
A night at Sardi`s announces 2011 Honoree
The 19th Annual "A Night at Sardi's," a star-studded benefit for the Alzheimer's Association on Wednesday, March 16, 2011 at the Beverly Hilton, will honor The Walt Disney Company's President and CEO Robert A. Iger for his contributions in the fight against Alzheimer's disease. Mr. Iger will receive the Abe Burrows Entertainment Award, which is presented to an individual who has shown an ...
-
Sage Therapeutics and Biogen to Host Investor Webcast on December 6, 2022 to Discuss Potential Commercialization Plans for Zuranolone
Sage Therapeutics, Inc. (Nasdaq: SAGE) and Biogen Inc. (Nasdaq: BIIB) today announced that the companies will host a joint investor webcast to discuss the planned commercialization approach and opportunity for their investigational product, zuranolone, on Tuesday, December 6 at 8:00 a.m. ET. Zuranolone is being evaluated as a potential rapid-acting, once-daily, oral two-week treatment for major ...
-
Optina Diagnostics and Wagner Macula Retina Center will Collaborate to Conduct a Clinical Study and Develop a Unique in-community Patient access Program Aimed to Identify the Causes of Memory Loss through Eye Diagnostics
Alzheimer’s awareness month, Optina Diagnostics and Wagner Macula Retina Center will Collaborate to Conduct a Clinical Study and Develop a Unique in-community Patient access Program Aimed to Identify the Causes of Memory Loss through Eye Diagnostics, November 6th 2019 Optina Diagnostics Optina Diagnostics, a world leading company in retinal imaging and artificial intelligence with a vision ...
-
DiamiR Receives USPTO Notice of Allowance For Key Patent Covering the Use of Circulating Brain-Enriched microRNA Biomarkers for Monitoring of Brain Aging; Provides Update on Its Patent Portfolio
DiamiR, a developer of innovative blood-based diagnostic tests for neurodegenerative and other diseases, today announced that it has received a notice of allowance from the United States Patent & Trademark Office (USPTO) for U.S. Patent Application No. 16/044,279 entitled "miRNA-based methods for detecting and monitoring aging." The patent covers the use of methods developed by DiamiR based ...
By DiamiR
-
DiamiR Receives USPTO Notice of Allowance For Key Patent Covering the Use of microRNA Biomarkers from Bodily Fluids for Diagnosis and Monitoring of Rett Syndrome and Other Neurodevelopmental Diseases
DiamiR, a developer of innovative blood-based diagnostic tests for brain health and other diseases, today announced that it has received a notice of allowance from the United States Patent & Trademark Office (USPTO) for U.S. Patent Application No. 16/028,206 entitled "Methods of using miRNA from bodily fluids for diagnosis and monitoring of neurodevelopmental disorders." The patent covers the ...
By DiamiR
-
How the brain-eye connection aims to make memory loss a souvenir
In fact, nearly 40% of people over the age of 65 suffer from some form of memory loss. Understanding the causes of memory loss There’s currently no cure for Alzheimer’s or Alzheimer’s related dementia, early detection can give patients more control over how they manage their overall well-being. That includes managing their brain health to reduce certain risk factors, ...
-
Altoida Partners With GN Group to Research and Develop New Cognitive Assessment Technology to Detect Mild Cognitive Impairment
Altoida, Inc. an AI company pioneering next-generation neurological disease diagnostics, and GN Group, a global leader in intelligent audio solutions, have signed a multi-year strategic partnership to research and develop new digital biomarkers for identifying Mild Cognitive Impairment (MCI). The research will serve as the backbone for new augmented reality tools to help at-risk individuals gain ...
-
DiamiR Announces Additional $345,000 Funding from the NIH for Development of CogniMIR
DiamiR, a developer of innovative blood-based diagnostic tests for neurodegenerative and other diseases, announced today that the National Institute on Aging (NIA) of the National Institutes of Health (NIH) has awarded DiamiR $345,000 in supplemental funding under the ongoing Small Business Innovation Research (SBIR) Phase IIB grant of $2,800,000 awarded in 2017. The award will further support ...
By DiamiR
-
Altoida upsizes its Series A Round to $20.3M to Advance Its First in Class AI-Powered Neurocognitive Assessment Platform
Altoida, Inc., the precision neurology company pioneering non-invasive brain health measurement and neurological disease diagnostics with AI and augmented reality (AR), today announced that it has successfully raised an additional $14 million for its Series A round with new and existing investors. The investment was co-led by M Ventures (the corporate venture capital arm of Merck KGaA, Darmstadt, ...
-
Optina Diagnostics Closes an Oversubscribed Series-A Round of CA$24.8 million
2021 Optina, an innovative diagnostics company leading the field of Retinal Imaging, Brain Health and Systemic Diseases Diagnostics, announced today the closing of an CA$24.8 million Series A round of funding. Optina’s Retinal Deep Phenotyping™ platform obtained FDA Breakthrough Device Designation status in 2019 for its non-invasive and more accessible test to improve diagnosis ...
-
ReGen Scientific First Health Institute in Canada to Introduce Evry™ into Proactive Brain Health Management and COVID-19 ‘Long-Hauler’ Research and Support
ReGen Scientific, a leader in personalized, preventative, and regenerative health announced today it will become the first comprehensive health clinic in Canada to bring Synaptive Medical’s Evry™, a superconducting 0.5T head magnetic resonance imaging (MRI) system intended to provide MRI directly at the point-of-care, to their downtown Toronto location. “Maintaining a healthy ...
-
Altoida Appoints Neuroscience Pioneer Dr. Antontella Santuccione Chadha as Chief Medical Officer
Altoida, Inc., a precision neurology company pioneering non-invasive brain health measurement and neurological disease diagnostics with AI and augmented reality (AR), today announced the appointment of Dr. Antonella Santuccione Chadha as Chief Medical Officer. In this new role, Dr. Chadha will lead all clinical and medical affairs as the company continues to develop, validate, and commercialize ...
-
Artificial Intelligence Expert Neil Sahota Joins Evoke Neuroscience Executive Advisory Board
NEWPORT BEACH, CA, USA, May 7, 2020 /EINPresswire.com/ — Evoke Neuroscience announced today that IBM Master Inventor, United Nations Artificial Intelligence (AI) Subject Matter Expert, and UC Irvine Professor Neil Sahota has joined the company’s executive advisory board. For the past 20 years, Neil has worked with Global Fortune 500 companies and world government leaders to foster ...
-
Optina Diagnostics and the Montreal Heart Institute Partner to Develop a New Biomarker for Atherosclerosis which could aid in the proper diagnosis of vascular dementia
Do you have senior moments? Are you concerned your memory loss may be a sign of something beyond normal aging? An innovative eye exam is helping physicians answer these questions with confidence. Optina Diagnostics, a world leader in retinal imaging technology and AI with a vision to change mindsets when it comes to brain health and Dr. Jean-Claude Tardif’s research group from the Montreal ...
-
Optina Diagnostics announces a collaborative clinical research study with the Alzheimer Center Amsterdam, Amsterdam UMC
Optina Diagnostics announces today that it has signed an agreement with the Alzheimer Center Amsterdam, part of the Amsterdam University Medical Center to pursue the study of Optina’s Retinal Deep Phenotyping Platform™? in a cohort of 100 subjects. July 29, 2020 Optina Diagnostics announces today that it has signed an agreement with the Alzheimer Center Amsterdam, part of the ...
-
DiamiR Biosciences Announces Participation in Alzheimer`s Panel at the BioFuture 2022 Conference
DiamiR, a developer of innovative blood-based diagnostic tests for brain health and other diseases, today announced that the company's management will participate in the BioFuture Conference being held on November 7-9, 2022 at the Lotte New York Palace in New York City, NY. Kira Sheinerman, Ph.D., Co-Founder and Executive Director, will be a participant in the panel discussion, "New approvals, ...
By DiamiR
-
Optina announces a US$2.1M investment from the Diagnostics Accelerator at the Alzheimer’s Drug Discovery Foundation (ADDF)
A collaborative research initiative supported by ADDF’s Co-Founder Leonard A. Lauder, Bill Gates, Jeff Bezos, MacKenzie Scott, the Dolby family, and the Charles and Helen Schwab Foundation, among others, to advance the most promising early diagnostics for Alzheimer’s disease. Optina, an innovative diagnostics company, leader in retinal imaging, brain health and systemic disease ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you